1. 3rd Workshop on Non-Clinical Safety Assessment of Biopharmaceuticals “Next generation therapies”
WELCOME

2. This meeting is sponsored by
Gold
Bronze

3. SPONSORS BELTOX
Gold
Silver
Bronze

4. Morning Session: Introductory lectures
8:50
Welcome JM. Wilkin, GSK Vaccines, Belgium
9:00
Nucleotide therapies: Past failures and future challenges L. Coney, Huntingdon Life Sciences, United Kingdom
9:40
Safety Evaluation of Gene Therapy Products including Inhaled Products M. Mc Elroy, Charles River Laboratories, United Kingdom
10:20
Regulatory perspective on the safety assessment of oligonucleotides and gene therapies C. Beuneu, Federal Agency for Medicines and Health Products, Belgium
10:45
Coffee break
11:05 
The personalized medicine approach in orphan disease: development of oligonucleotides for the treatment of Duchenne’s Muscular Dystrophy C. den Besten, Prosensa, The Netherlands
11:35
Non-GLP Pharmacology and the GLP Toxicology Studies to support the use of CpG as adjuvant in anti-nicotine and anti-IgE therapeutic vaccines M. McCluskie, Pfizer, Canada
12:15
Toxicologic pathology of antisense oligonucleotides C. Sobry, CitoxLab, France
12:5
Lunch and networking

5. Afternoon Session: Case studies analysis
13:45
Introduction to breakout sessions
14:00
Breakout sessions
15:00
Coffee break
15:20
Case study reporting and discussion
16:50
Concluding remarks M. Martens, President Beltox